{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:54:36Z","timestamp":1782352476271,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40263-021-00852-7","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T16:45:04Z","timestamp":1628527504000},"page":"1023-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain"],"prefix":"10.1007","volume":"35","author":[{"given":"Juan C.","family":"Pascual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-0854","authenticated-orcid":false,"given":"Ana","family":"Mart\u00edn-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"issue":"4","key":"852_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4088\/jcp.v69n0404","volume":"69","author":"BF Grant","year":"2008","unstructured":"Grant BF, Chou SP, Goldstein RB, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69(4):533\u201345. https:\/\/doi.org\/10.4088\/jcp.v69n0404.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"852_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1521\/pedi.2010.24.4.412","volume":"24","author":"TJ Trull","year":"2010","unstructured":"Trull TJ, Jahng S, Tomko RL, et al. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24(4):412\u201326. https:\/\/doi.org\/10.1521\/pedi.2010.24.4.412.","journal-title":"J Pers Disord"},{"issue":"5","key":"852_CR3","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1521\/pedi_2016_30_269","volume":"31","author":"I Alvarez-Tom\u00e1s","year":"2017","unstructured":"Alvarez-Tom\u00e1s I, Soler J, Bados A, et al. Long-term course of borderline personality disorder: a prospective 10-year follow-up study. J Pers Disord. 2017;31(5):590\u2013605. https:\/\/doi.org\/10.1521\/pedi_2016_30_269.","journal-title":"J Pers Disord"},{"issue":"8","key":"852_CR4","doi-asserted-by":"publisher","first-page":"CD005652","DOI":"10.1002\/14651858.CD005652.pub2","volume":"2012","author":"JM Stoffers","year":"2012","unstructured":"Stoffers JM, V\u00f6llm BA, R\u00fccker G, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012;2012(8):CD005652. https:\/\/doi.org\/10.1002\/14651858.CD005652.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"852_CR5","doi-asserted-by":"publisher","first-page":"CD012955","DOI":"10.1002\/14651858.CD012955.pub2","volume":"5","author":"OJ Storeb\u00f8","year":"2020","unstructured":"Storeb\u00f8 OJ, Stoffers-Winterling JM, V\u00f6llm BA, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020;5(5):CD012955. https:\/\/doi.org\/10.1002\/14651858.CD012955.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"852_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/YIC.0b013e32833e23ed","volume":"25","author":"JC Pascual","year":"2010","unstructured":"Pascual JC, Mart\u00edn-Blanco A, Soler J, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol. 2010;25(6):349\u201355. https:\/\/doi.org\/10.1097\/YIC.0b013e32833e23ed.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"852_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/acps.12767","volume":"136","author":"A Mart\u00edn-Blanco","year":"2017","unstructured":"Mart\u00edn-Blanco A, Ancochea A, Soler J, et al. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand. 2017;136(3):323\u201331. https:\/\/doi.org\/10.1111\/acps.12767.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"852_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","volume":"23","author":"F Riffer","year":"2019","unstructured":"Riffer F, Farkas M, Streibl L, et al. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract. 2019;23(3):178\u201388. https:\/\/doi.org\/10.1080\/13651501.2019.1576904.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"852_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","volume":"6","author":"S Simonsen","year":"2019","unstructured":"Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregul. 2019;6:9. https:\/\/doi.org\/10.1186\/s40479-019-0106-3.","journal-title":"Borderline Personal Disord Emot Dysregul."},{"issue":"10 Suppl","key":"852_CR10","first-page":"1","volume":"158","author":"American Psychiatric Association Practice Guidelines","year":"2001","unstructured":"American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(10 Suppl):1\u201352.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"852_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/15622970701685224","volume":"8","author":"SC Herpertz","year":"2007","unstructured":"Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8(4):212\u201344. https:\/\/doi.org\/10.1080\/15622970701685224.","journal-title":"World J Biol Psychiatry."},{"key":"852_CR12","unstructured":"DGPPN. Deutsche Gesellschaft f\u00fcr Psychiatry, Psychotherapie und Nervenheilkunde. Behandlungsleitlinie Pers\u00f6nlichkeitst\u00f6rungen [German guideline for personality disorders]. Dresden: Steinkopff Verlag; 2009."},{"key":"852_CR13","volume-title":"Multidisciplinaire Richtlijn voor de diagnostiek en behandeling van volwassen pati\u00ebnten met een persoonlijkheidsstorrnis [Dutch multidisciplinary guideline for the diagnosis and treatment of personality disorders]","author":"CBO Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ","year":"2008","unstructured":"CBO Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ. Multidisciplinaire Richtlijn voor de diagnostiek en behandeling van volwassen pati\u00ebnten met een persoonlijkheidsstorrnis [Dutch multidisciplinary guideline for the diagnosis and treatment of personality disorders]. Utrecht: Trimbos-instituut; 2008."},{"key":"852_CR14","unstructured":"National Institute for Clinical Excellence (NICE). Borderline personality disorder: treatment and management. Clinical Guideline. London: NICE; 2009."},{"key":"852_CR15","unstructured":"National Health and Medical Research Council. Clinical Practice Guideline for the Management of Borderline Personality Disorder. Canberra: National Health and Medical Research Council; 2012."},{"key":"852_CR16","unstructured":"GPC. Grupo de trabajo de la gu\u00eda de pr\u00e1ctica cl\u00ednica sobre trastorno l\u00edmite de la personalidad. F\u00f3rum de Salud Mental y AIAQS, coordinadores. Gu\u00eda de pr\u00e1ctica cl\u00ednica sobre trastorno l\u00edmite de la personalidad. Barcelona: Ag\u00e8ncia d\u2019Informaci\u00f3, Avaluaci\u00f3 i Qualitat en Salut. Servei Catal\u00e0 de la Salut. Pla Director de Salut Mental i Addiccions. Departament de Salut. Generalitat de Catalunya; 2011."},{"issue":"1","key":"852_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0000000000000232","volume":"35","author":"MC Zanarini","year":"2015","unstructured":"Zanarini MC, Frankenburg FR, Reich DB, Harned AL, Fitzmaurice GM. Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. J Clin Psychopharmacol. 2015;35(1):63\u20137. https:\/\/doi.org\/10.1097\/JCP.0000000000000232.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"852_CR18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1600-0447.2011.01728.x","volume":"124","author":"MJ Crawford","year":"2011","unstructured":"Crawford MJ, Kakad S, Rendel C, et al. Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting. Acta Psychiatr Scand. 2011;124(5):396\u2013402. https:\/\/doi.org\/10.1111\/j.1600-0447.2011.01728.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"852_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, H\u00e4berle A, M\u00fcller ST, Cattapan K, Grohmann R, Toto S, Kasper S, Greil W. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(6):763\u201372. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.017.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"852_CR20","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.4088\/JCP.14m09228","volume":"76","author":"C Paton","year":"2015","unstructured":"Paton C, Crawford MJ, Bhatti SF, et al. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76(4):e512\u20138. https:\/\/doi.org\/10.4088\/JCP.14m09228.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"852_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1176\/appi.ajp.2020.19091000","volume":"177","author":"TG Rhee","year":"2020","unstructured":"Rhee TG, Olfson M, Nierenberg AA, et al. 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry. 2020;177(8):706\u201315. https:\/\/doi.org\/10.1176\/appi.ajp.2020.19091000.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"852_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11920-020-01164-1","volume":"22","author":"J Stoffers-Winterling","year":"2020","unstructured":"Stoffers-Winterling J, Storeb\u00f8 OJ, Lieb K. Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep. 2020;22(8):37. https:\/\/doi.org\/10.1007\/s11920-020-01164-1.","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"852_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1521\/pedi.1994.8.2.104","volume":"8","author":"M G\u00f3mez-Beneyto","year":"1994","unstructured":"G\u00f3mez-Beneyto M, Villar M, Renovell M, et al. The Diagnosis of Personality Disorder with a modified version of the SCID-II in a Spanish clinical sample. J Pers Disord. 1994;8(2):104\u201310. https:\/\/doi.org\/10.1521\/pedi.1994.8.2.104.","journal-title":"J Pers Disord"},{"issue":"5","key":"852_CR24","first-page":"293","volume":"32","author":"J Barrachina","year":"2004","unstructured":"Barrachina J, Soler J, Campins MJ, et al. Validaci\u00f3n de la versi\u00f3n espa\u00f1ola de la Diagnostic Interview for Bordelines-Revised (DIB-R) [Validation of a Spanish version of the Diagnostic Interview for Bordelines-Revised (DIB-R)]. Actas Esp Psiquiatr. 2004;32(5):293\u20138.","journal-title":"Actas Esp Psiquiatr"},{"key":"852_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2013","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. New York: Wiley; 2013.","edition":"3"},{"issue":"9","key":"852_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1176\/ps.2007.58.9.1199","volume":"58","author":"JC Pascual","year":"2007","unstructured":"Pascual JC, C\u00f3rcoles D, Casta\u00f1o J, et al. Hospitalization and pharmacotherapy for borderline personality disorder in a psychiatric emergency service. Psychiatr Serv. 2007;58(9):1199\u2013204. https:\/\/doi.org\/10.1176\/ps.2007.58.9.1199.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"852_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12888-019-2377-z","volume":"19","author":"C Tim\u00e4us","year":"2019","unstructured":"Tim\u00e4us C, Meiser M, Bandelow B, et al. Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry. 2019;19(1):393. https:\/\/doi.org\/10.1186\/s12888-019-2377-z.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"852_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/JCP.0b013e3182217a69","volume":"31","author":"TJ Ingenhoven","year":"2011","unstructured":"Ingenhoven TJ, Duivenvoorden HJ. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 2011;31(4):489\u201396. https:\/\/doi.org\/10.1097\/JCP.0b013e3182217a69.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"852_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1176\/appi.ajp.2018.17091006","volume":"175","author":"MJ Crawford","year":"2018","unstructured":"Crawford MJ, Sanatinia R, Barrett B, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018;175(8):756\u201364. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17091006.","journal-title":"Am J Psychiatry"},{"key":"852_CR30","volume-title":"Handbook of good psychiatric management for borderline personality disorder","author":"JG Gunderson","year":"2014","unstructured":"Gunderson JG, Links PS. Handbook of good psychiatric management for borderline personality disorder. 1st ed. Washington DC: American Psychiatric Publishing; 2014.","edition":"1"},{"issue":"4","key":"852_CR31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14com09441","volume":"76","author":"J Paris","year":"2015","unstructured":"Paris J. Why patients with severe personality disorders are overmedicated. J Clin Psychiatry. 2015;76(4): e521. https:\/\/doi.org\/10.4088\/JCP.14com09441.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"852_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/HRP.0000000000000200","volume":"27","author":"SK Fineberg","year":"2019","unstructured":"Fineberg SK, Gupta S, Leavitt J. Collaborative deprescribing in borderline personality disorder: a narrative review. Harv Rev Psychiatry. 2019;27(2):75\u201386. https:\/\/doi.org\/10.1097\/HRP.0000000000000200.","journal-title":"Harv Rev Psychiatry"},{"key":"852_CR33","volume-title":"Cognitive-behavioral treatment of borderline personality disorder","author":"M Linehan","year":"1993","unstructured":"Linehan M. Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press; 1993."},{"key":"852_CR34","doi-asserted-by":"crossref","unstructured":"Burckell L, McMain S. Dialectical behavior therapy adapted to the treatment of concurrent borderline personality disorder and substance use disorders. Clinical Addiction Psychiatry. 2010:207\u2013217.","DOI":"10.1017\/CBO9780511782107.022"},{"key":"852_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112671","volume":"284","author":"T Nguyen","year":"2020","unstructured":"Nguyen T, Seiler N, Brown E, et al. The effect of Clinical Practice Guidelines on prescribing practice in mental health: a systematic review. Psychiatry Res. 2020;284: 112671. https:\/\/doi.org\/10.1016\/j.psychres.2019.112671.","journal-title":"Psychiatry Res"},{"issue":"6","key":"852_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/pds.4551","volume":"27","author":"T Kurko","year":"2018","unstructured":"Kurko T, Saastamoinen LK, Tuulio-Henriksson A, et al. Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: a national register study for 2006 to 2014. Pharmacoepidemiol Drug Saf. 2018;27(6):674\u201382. https:\/\/doi.org\/10.1002\/pds.4551.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"852_CR37","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/pds.4187","volume":"26","author":"K Kochi","year":"2017","unstructured":"Kochi K, Sato I, Nishiyama C, Tanaka-Mizuno S, Doi Y, Arai M, et al. Trends in antipsychotic prescriptions for Japanese outpatients during 2006\u20132012: a descriptive epidemiological study. Pharmacoepidemiol Drug Saf. 2017;26(6):642\u201356. https:\/\/doi.org\/10.1002\/pds.4187.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00852-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00852-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00852-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T12:59:48Z","timestamp":1630414788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00852-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00852-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"20 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no funding sources to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Juan C. Pascual, Ana Mart\u00edn-Blanco, and Joaquim Soler declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All three authors contributed equally to designing and conducting the study, analyzing the data, and writing this article. All authors approved the final version of the manuscript for submission and agree to be accountable for the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This study adhered to the principles outlined in the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee at the Hospital de la Santa Creu I Sant Pau.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written consent to participate in this study was not considered necessary as all data were collected retrospectively from routine admission data and were anonymized; however, the authors did check the patients\u2019 medical records to ensure that there was no written objection to the use of this information.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}